tyrosine kinase inhibitor

You have access
Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future
MICHAEL STOTZ, ARMIN GERGER, JOHANNES HAYBAECK, TOBIAS KIESSLICH, MARC D. BULLOCK and MARTIN PICHLER

Anticancer Research November 2015, 35 (11) 5737-5744;
You have access
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer
MARYE J. BOERS-SONDEREN, INGRID M.E. DESAR, JURGEN J. FÜTTERER, SASJA F. MULDER, LIOE-FEE DE GEUS-OEI, PETER F. MULDERS, WINETTE T.A. VAN DER GRAAF, WIM J.G. OYEN and CARLA M.L. VAN HERPEN

Anticancer Research October 2015, 35 (10) 5601-5606;
You have access
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma
AKIRA MIYAZAKI, HIDEAKI MIYAKE, KEN-ICHI HARADA and MASATO FUJISAWA

Anticancer Research May 2015, 35 (5) 3067-3073;
You have access
Small Molecules Alter VEGFR and PTEN Expression in HPV-positive and -negative SCC: New Hope for Targeted-therapy
CHRISTOPH ADERHOLD, ANNE FABER, CLAUDIA UMBREIT, ANJA CHAKRABORTY, ANDRE BOCKMAYER, RICHARD BIRK, JÖRG ULRICH SOMMER, KARL HÖRMANN and JOHANNES DAVID SCHULTZ

Anticancer Research March 2015, 35 (3) 1389-1399;
You have access
The Angiopoietin-Tie2 Pathway Is a Potential Therapeutic Target in Urothelial Carcinoma
WEIGUO JIAN, JONATHAN M. LEVITT, SETH P. LERNER and GURU SONPAVDE

Anticancer Research July 2014, 34 (7) 3377-3382;
You have access
Survival of Patients Undergoing Cytoreductive Surgery for Metastatic Renal Cell Carcinoma in the Targeted-Therapy Era
MICHAEL R. ABERN, EMELIAN SCOSYREV, MATVEY TSIVIAN, EDWARD M. MESSING, THOMAS J. POLASCIK and ARKADIUSZ Z. DUDEK

Anticancer Research May 2014, 34 (5) 2405-2411;
You have access
Small Molecule-based Chemotherapeutic Approach in p16-positive and -negative HNSCC In Vitro
CHRISTOPH ADERHOLD, ANNE FABER, GUIDO MANUEL GROBSCHMIDT, ANJA CHAKRABORTY, ANDRE BOCKMAYER, CLAUDIA UMBREIT, RICHARD BIRK, JENS STERN-STRAETER, KARL HÖRMANN and JOHANNES DAVID SCHULTZ

Anticancer Research December 2013, 33 (12) 5385-5393;
You have access
Outcome of Allotransplants in Patients with Chronic-phase Chronic Myeloid Leukemia Following Imatinib Failure: Prognosis Revisited
YI-CHANG LIU, HUI-HUA HSIAO, CHAO-SUNG CHANG, TA-CHIH LIU, WEN-CHI YANG, JUI-FENG HSU, CHIUNG-TANG HUANG, SHIH-FENG CHO, CHENG-HAN WU, YU-FEN TSAI and SHENG-FUNG LIN

Anticancer Research October 2013, 33 (10) 4663-4667;
You have access
Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Requires E-Cadherin in Esophageal Cancer and Malignant Pleural Mesothelioma
HONG-WU XIN, JIAN-HUI YANG and DAO M. NGUYEN

Anticancer Research June 2013, 33 (6) 2401-2408;
You have access
Evaluation of the KIT/Stem Cell Factor Axis in Renal Tumours
MARKUS HORSTMANN, JOERG HENNENLOTTER, LISA M. GEIGER, ULRICH VOGEL, HEIDI SCHMID, URSULA KUEHS, ARNULF STENZL and JENS BEDKE

Anticancer Research October 2012, 32 (10) 4339-4345;

Main menu

User menu

Search

tyrosine kinase inhibitor

Pages